AORT vs MASI

For growth investors, Artivion, Inc.

(AORT) is the stronger pick with 13. 6% revenue growth year-over-year, versus -27. 1% for Masimo Corporation (MASI). Artivion, Inc. (AORT) offers the better valuation at 168. 5x trailing P/E (75. 3x forward), making it the more compelling value choice. Analysts rate Artivion, Inc. (AORT) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Masimo Corporation is actually cheaper at 32.

4x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Artivion, Inc.

(AORT) delivered a total return of +15. 4%, compared to -20. 4% for Masimo Corporation (MASI). Over 10 years, the gap is even starker: MASI returned +282. 5% versus AORT's +107. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Artivion, Inc.

(AORT) is the lower-risk stock at 0. 57β versus Masimo Corporation's 0. 61β — meaning MASI is approximately 6% more volatile than AORT relative to the S&P 500. On balance sheet safety, Artivion, Inc. (AORT) carries a lower debt/equity ratio of 65% versus 78% for Masimo Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Artivion, Inc.

(AORT) is pulling ahead at 13. 6% versus -27. 1% for Masimo Corporation (MASI). On earnings-per-share growth, the picture is similar: Artivion, Inc. grew EPS 165. 6% year-over-year, compared to 51. 0% for Masimo Corporation. Over a 3-year CAGR, AORT leads at 12. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Artivion, Inc.

(AORT) is the more profitable company, earning 2. 2% net margin versus -9. 9% for Masimo Corporation — meaning it keeps 2. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MASI leads at 20. 5% versus 6. 1% for AORT. At the gross margin level — before operating expenses — MASI leads at 61. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Masimo Corporation (MASI) trades at 32.

4x forward P/E versus 75. 3x for Artivion, Inc. — 42. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AORT: 49. 8% to $53. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Masimo Corporation (MASI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

61), +282. 5% 10Y return). Both have compounded well over 10 years (MASI: +282. 5%, AORT: +107. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.